Shares of Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH – Get Rating) have received an average rating of “Buy” from the three research firms that are currently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price […]
Longboard Pharmaceuticals (NASDAQ:LBPH – Get Rating)‘s stock had its “overweight” rating restated by research analysts at Cantor Fitzgerald in a report issued on Friday, Zacks.com reports. Several other research firms have also recently issued reports on LBPH. Zacks Investment Research raised shares of Longboard Pharmaceuticals from a “sell” rating to a “hold” rating in a […]
Two poster presentations highlight Phase 1 data for LP352 in healthy volunteers SAN DIEGO, April 01, 2022 Longboard Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company. | April 1, 2022
Pipeline Advancement Continues with Ongoing Phase 2 Studies for Voriconazole and Tacrolimus Programs Partnership Activity Surrounding Thin Film Freezing.